Immunophotonics co-founders Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President are pleased to announce the appointment of Dr. Maziar Assadi Gehr in the role of Medical Director. Dr. Gehr will spearhead the development of our pivotal trial, drawing upon his extensive expertise in various facets of the drug development process, including biomarker research,...
Immunophotonics, Inc. is delighted to introduce Jacqueline Hess as the newest addition to our advisory board. Ms. Hess has over 25 years of Big 4 experience supporting U.S. biotech companies that are expanding globally, with a particular focus on the U.S.-Swiss business corridor. Jacqueline is dedicated to helping life sciences companies thrive and achieve their mission of helping...
Tomas Hode, PhD, who serves as the Co-Founder, CIO, and President at Immunophotonics, Inc., will be attending the European Conference on Interventional Oncology (ECIO 2024) in Palma de Mallorca, Spain, from April 28-May 1. To learn more about how Immunophotonics continues to explore the ability of IP-001 to transform a routine interventional-oncology procedure into a...
Immunophotonics is thrilled to share that Dr. Theresa Visarius from Immunophotonics Switzerland (IPS Biopharma) will be attending the Swiss Biotech Day 2024 in Basel, Switzerland, on April 22 – 23. Joining her will be our new Immunophotonics advisor, Jacqueline Hess. Don’t miss her poster presentation showcasing how Immunophotonics is advancing the novel concept of abscopalizing...
Tomas Hode, PhD, who serves as the Co-Founder, CIO, and President at Immunophotonics, Inc. is eager to attend the AngioDynamics International Life Symposium “The Human Touch, Behind Innovation” scheduled for March 21-23 in Rome. At this event, he will be engaging with clinical experts and industry partners on the latest technologies for surgical interventions.
Immunophotonics to be showcased as the Member Highlight for March by The Missouri Biotechnology Association (MOBIO), both on their homepage and in the March newsletter. MOBIO serves as a representative body for all Missouri entities engaged in life sciences, innovation, and entrepreneurship, promoting advancements in life science research, and fostering economic development. This recognition provides...
Immunophotonics Lu Alleruzzo, CEO and Tomas Hode, PhD, CIO, and President have announced a partnership that will combine use of Immunophotonics’ lead asset, IP-001 and AngioDynamics’ ablation devices to explore the power of ablation in combination with immunotherapy for the treatment of solid tumor cancers. This collaborative effort extends to a partnership with the Cancer...
Immunophotonics, Inc. is grateful to NCI (National Cancer Institute) SBIR Investor Initiatives Team for providing us the opportunity to showcase our technology at the Global Life Science Partnering & Investor Conference presented by BIOCOM California taking place February 27 – 29, 2024 in La Jolla, California. Immunophotonics is thrilled to take part in this exclusive...
Congratulations to Professor Wei Chen and his lab at the University of Oklahoma, along with contributors Lu Alleruzzo, Samuel S.K. Lam, and Tomas Hode of Immunophotonics, for their publication titled “N-dihydrogalactochitosan serves as an effective mucosal adjuvant for intranasal vaccine in combination with recombinant viral proteins against respiratory infection” in Acta Biomaterialia, an international journal,...
St. Louis cancer drug startup Immunophotonics Inc. will pursue expansion of its lead drug candidate through a partnership with the innovation arm of pharmaceutical giant Johnson & Johnson. (St. Louis INNO/Business Journal article)
